937 related articles for article (PubMed ID: 2946711)
41. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
Cameron ST; Thong KJ; Baird DT
Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
[TBL] [Abstract][Full Text] [Related]
42. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
43. Effect of daily administration of 0.5 mg. of chlormadinone acetate on plasma levels of follicle-stimulating hormone, luteinizing hormone, and progesterone during the menstrual cycle.
Saunders DM; Marcus SL; Saxena BB; Beling CG; Connell EB
Fertil Steril; 1971 May; 22(5):332-44. PubMed ID: 4102481
[TBL] [Abstract][Full Text] [Related]
44. Response to intermittent RU486 in women.
Spitz IM; Croxatto HB; Salvatierra AM; Heikinheimo O
Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
[TBL] [Abstract][Full Text] [Related]
45. Effects of intermittent antiprogestin RU486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation.
Kekkonen R; Croxatto HB; Lähteenmäki P; Salvatierra AM; Tuominen J
Hum Reprod; 1995 Feb; 10(2):287-92. PubMed ID: 7769050
[TBL] [Abstract][Full Text] [Related]
46. Cyclic administration of an LHRH analogue and of progesterone in risk patients to oral contraceptives.
Geisthoevel F; Jenne D; Wieacker P; Breckwoldt M
Contraception; 1987 Oct; 36(4):459-69. PubMed ID: 3127113
[TBL] [Abstract][Full Text] [Related]
47. Luteolytic activity of LHRH and [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide: a new and physiological approach to contraception in women.
Lemay A; Labrie F; Raynaud JP
Int J Fertil; 1980; 25(3):203-12. PubMed ID: 6108931
[TBL] [Abstract][Full Text] [Related]
48. [Contraception by cyclic treatment with buserelin and progesterone].
Wieacker P; Breckwoldt M; Greif M; Geisthövel F
Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):135-9. PubMed ID: 1904039
[TBL] [Abstract][Full Text] [Related]
49. The effect of norethisterone (500 mcg) and ethinyl estradiol (35 mcg) capsules on the pituitary-ovarian axis.
Nuttall ID; Elstein M; Fahmy DR
Contraception; 1982 May; 25(5):463-9. PubMed ID: 6809424
[TBL] [Abstract][Full Text] [Related]
50. Gonadotropin, steroid, and inhibin levels in women with incipient ovarian failure during anovulatory and ovulatory rebound cycles.
Buckler HM; Evans CA; Mamtora H; Burger HG; Anderson DC
J Clin Endocrinol Metab; 1991 Jan; 72(1):116-24. PubMed ID: 1824706
[TBL] [Abstract][Full Text] [Related]
51. Intranasal LHRH agonist (Buserelin) after ovulation: a post-coital contraceptive approach.
Lemay A; Faure N; Labrie F; Fazekas AT
Contracept Deliv Syst; 1983 Apr; 4(2):107-25. PubMed ID: 12338631
[TBL] [Abstract][Full Text] [Related]
52. GnRH agonist administration in polycystic ovary syndrome.
Buckler HM; Phillips SE; Kovacs GT; Burger HG; Healy DL
Clin Endocrinol (Oxf); 1989 Aug; 31(2):151-65. PubMed ID: 2514053
[TBL] [Abstract][Full Text] [Related]
53. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
[TBL] [Abstract][Full Text] [Related]
54. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
55. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
56. Effects of combined oral contraceptive steroids on pituitary-ovarian function during the menstrual cycle of lactating women.
Ryu K; Yu HK; Kwak HM; Hong SS
Contraception; 1983 Mar; 27(3):299-310. PubMed ID: 6406140
[TBL] [Abstract][Full Text] [Related]
57. Chronic treatment with a LH-RH-agonist: a new contraceptive method?
Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J
Acta Eur Fertil; 1981 Sep; 12(3):275-6. PubMed ID: 6803498
[TBL] [Abstract][Full Text] [Related]
58. Serum inhibin levels in polycystic ovary syndrome: basal levels and response to luteinizing hormone-releasing hormone agonist and exogenous gonadotropin administration.
Buckler HM; McLachlan RI; MacLachlan VB; Healy DL; Burger HG
J Clin Endocrinol Metab; 1988 Apr; 66(4):798-803. PubMed ID: 3126215
[TBL] [Abstract][Full Text] [Related]
59. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
Bergquist C; Nillius SJ; Wide L
Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
[TBL] [Abstract][Full Text] [Related]
60. Laboratory criteria for menopause in women using oral contraceptives.
Creinin MD
Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
